{"id":"nirmatrelvir-ritonavir","rwe":[],"tags":[],"safety":{"safetySignals":[{"date":"","signal":"DRUG INTERACTION","source":"FDA FAERS","actionTaken":"Reported 317 times"},{"date":"","signal":"OFF LABEL USE","source":"FDA FAERS","actionTaken":"Reported 208 times"},{"date":"","signal":"COVID-19","source":"FDA FAERS","actionTaken":"Reported 179 times"},{"date":"","signal":"ACUTE KIDNEY INJURY","source":"FDA FAERS","actionTaken":"Reported 151 times"},{"date":"","signal":"DIARRHOEA","source":"FDA FAERS","actionTaken":"Reported 150 times"},{"date":"","signal":"TOXICITY TO VARIOUS AGENTS","source":"FDA FAERS","actionTaken":"Reported 139 times"},{"date":"","signal":"NAUSEA","source":"FDA FAERS","actionTaken":"Reported 135 times"},{"date":"","signal":"DYSGEUSIA","source":"FDA FAERS","actionTaken":"Reported 122 times"},{"date":"","signal":"HEPATIC FUNCTION ABNORMAL","source":"FDA FAERS","actionTaken":"Reported 117 times"},{"date":"","signal":"VOMITING","source":"FDA FAERS","actionTaken":"Reported 109 times"}],"drugInteractions":[{"drug":"Atorvastatin","action":"Avoid","effect":"Increased risk of myopathy and rhabdomyolysis"},{"drug":"Buprenorphine","action":"Monitor","effect":"Increased risk of central nervous system (CNS) depression"},{"drug":"Cyclosporine","action":"Monitor","effect":"Increased risk of nephrotoxicity"},{"drug":"Digoxin","action":"Monitor","effect":"Increased risk of digoxin toxicity"},{"drug":"Ergot alkaloids","action":"Avoid","effect":"Increased risk of ergotism"},{"drug":"Fentanyl","action":"Monitor","effect":"Increased risk of CNS depression"},{"drug":"HMG-CoA reductase inhibitors (e.g., simvastatin)","action":"Avoid","effect":"Increased risk of myopathy and rhabdomyolysis"},{"drug":"Lopinavir/ritonavir","action":"Monitor","effect":"Increased risk of adverse reactions"},{"drug":"Midazolam","action":"Monitor","effect":"Increased risk of CNS depression"},{"drug":"Pimozide","action":"Avoid","effect":"Increased risk of QT interval prolongation"},{"drug":"Prazosin","action":"Monitor","effect":"Increased risk of hypotension"},{"drug":"Rifampicin","action":"Avoid","effect":"Decreased nirmatrelvir and ritonavir plasma concentrations"},{"drug":"Sildenafil","action":"Monitor","effect":"Increased risk of hypotension"},{"drug":"Tacrolimus","action":"Monitor","effect":"Increased risk of nephrotoxicity"},{"drug":"Triazolam","action":"Monitor","effect":"Increased risk of CNS depression"}],"commonSideEffects":[{"effect":"Impaired sense of taste / Bitterness","drugRate":"60.5%","placeboRate":"","totalAtRisk":2005,"totalAffected":1214,"trialsReporting":1},{"effect":"Dysgeusia","drugRate":"7.0%","placeboRate":"","totalAtRisk":5391,"totalAffected":380,"trialsReporting":5},{"effect":"Diarrhea","drugRate":"18.2%","placeboRate":"","totalAtRisk":2005,"totalAffected":365,"trialsReporting":1},{"effect":"Diarrhoea","drugRate":"4.0%","placeboRate":"","totalAtRisk":5102,"totalAffected":202,"trialsReporting":4},{"effect":"Nausea","drugRate":"2.0%","placeboRate":"","totalAtRisk":5102,"totalAffected":103,"trialsReporting":4},{"effect":"Headache","drugRate":"1.4%","placeboRate":"","totalAtRisk":7107,"totalAffected":96,"trialsReporting":5},{"effect":"Muscle aches","drugRate":"4.4%","placeboRate":"","totalAtRisk":2005,"totalAffected":88,"trialsReporting":1},{"effect":"dysgeusia","drugRate":"61.8%","placeboRate":"","totalAtRisk":102,"totalAffected":63,"trialsReporting":1},{"effect":"Taste disorder","drugRate":"1.9%","placeboRate":"","totalAtRisk":3152,"totalAffected":59,"trialsReporting":2},{"effect":"COVID-19","drugRate":"2.4%","placeboRate":"","totalAtRisk":2273,"totalAffected":55,"trialsReporting":3},{"effect":"diarrhoea","drugRate":"50.0%","placeboRate":"","totalAtRisk":102,"totalAffected":51,"trialsReporting":1},{"effect":"Fibrin D dimer increased","drugRate":"0.9%","placeboRate":"","totalAtRisk":5102,"totalAffected":47,"trialsReporting":4},{"effect":"Stomach/Abdominal pain","drugRate":"2.3%","placeboRate":"","totalAtRisk":2005,"totalAffected":47,"trialsReporting":1},{"effect":"headache","drugRate":"44.1%","placeboRate":"","totalAtRisk":102,"totalAffected":45,"trialsReporting":1},{"effect":"Nausea/Vomiting","drugRate":"2.2%","placeboRate":"","totalAtRisk":2005,"totalAffected":44,"trialsReporting":1},{"effect":"Vomiting","drugRate":"1.0%","placeboRate":"","totalAtRisk":4190,"totalAffected":41,"trialsReporting":3},{"effect":"fatigue","drugRate":"35.3%","placeboRate":"","totalAtRisk":102,"totalAffected":36,"trialsReporting":1},{"effect":"Dizziness","drugRate":"0.5%","placeboRate":"","totalAtRisk":6195,"totalAffected":34,"trialsReporting":4},{"effect":"Cough","drugRate":"0.5%","placeboRate":"","totalAtRisk":7107,"totalAffected":32,"trialsReporting":5},{"effect":"myalgia","drugRate":"28.4%","placeboRate":"","totalAtRisk":102,"totalAffected":29,"trialsReporting":1},{"effect":"Fatigue","drugRate":"2.1%","placeboRate":"","totalAtRisk":1361,"totalAffected":28,"trialsReporting":2},{"effect":"nausea","drugRate":"25.5%","placeboRate":"","totalAtRisk":102,"totalAffected":26,"trialsReporting":1},{"effect":"dyspnoea","drugRate":"24.5%","placeboRate":"","totalAtRisk":102,"totalAffected":25,"trialsReporting":1},{"effect":"Decreased appetite","drugRate":"0.6%","placeboRate":"","totalAtRisk":4190,"totalAffected":24,"trialsReporting":3},{"effect":"Upper respiratory tract infection","drugRate":"1.1%","placeboRate":"","totalAtRisk":2273,"totalAffected":24,"trialsReporting":3},{"effect":"Alanine aminotransferase increased","drugRate":"1.1%","placeboRate":"","totalAtRisk":2273,"totalAffected":24,"trialsReporting":3},{"effect":"Constipation","drugRate":"0.5%","placeboRate":"","totalAtRisk":4190,"totalAffected":22,"trialsReporting":3},{"effect":"decreased appetite","drugRate":"21.6%","placeboRate":"","totalAtRisk":102,"totalAffected":22,"trialsReporting":1},{"effect":"Pyrexia","drugRate":"0.5%","placeboRate":"","totalAtRisk":4190,"totalAffected":21,"trialsReporting":3},{"effect":"Blood thyroid stimulating hormone increased","drugRate":"0.9%","placeboRate":"","totalAtRisk":2273,"totalAffected":21,"trialsReporting":3},{"effect":"abdominal pain","drugRate":"20.6%","placeboRate":"","totalAtRisk":102,"totalAffected":21,"trialsReporting":1},{"effect":"Rash","drugRate":"0.5%","placeboRate":"","totalAtRisk":4190,"totalAffected":20,"trialsReporting":3},{"effect":"Activated partial thromboplastin time prolonged","drugRate":"0.9%","placeboRate":"","totalAtRisk":2273,"totalAffected":20,"trialsReporting":3},{"effect":"Abdominal pain","drugRate":"0.5%","placeboRate":"","totalAtRisk":4190,"totalAffected":19,"trialsReporting":3},{"effect":"Malaise","drugRate":"0.6%","placeboRate":"","totalAtRisk":3152,"totalAffected":18,"trialsReporting":2},{"effect":"brain fog","drugRate":"17.6%","placeboRate":"","totalAtRisk":102,"totalAffected":18,"trialsReporting":1},{"effect":"Nasopharyngitis","drugRate":"0.7%","placeboRate":"","totalAtRisk":2273,"totalAffected":17,"trialsReporting":3},{"effect":"chest pain","drugRate":"16.7%","placeboRate":"","totalAtRisk":102,"totalAffected":17,"trialsReporting":1},{"effect":"dizziness","drugRate":"16.7%","placeboRate":"","totalAtRisk":102,"totalAffected":17,"trialsReporting":1},{"effect":"insomnia","drugRate":"16.7%","placeboRate":"","totalAtRisk":102,"totalAffected":17,"trialsReporting":1},{"effect":"Insomnia","drugRate":"0.4%","placeboRate":"","totalAtRisk":4190,"totalAffected":16,"trialsReporting":3},{"effect":"Hypertension","drugRate":"0.4%","placeboRate":"","totalAtRisk":4190,"totalAffected":16,"trialsReporting":3},{"effect":"oropharyngeal pain","drugRate":"15.7%","placeboRate":"","totalAtRisk":102,"totalAffected":16,"trialsReporting":1},{"effect":"Asthenia","drugRate":"0.7%","placeboRate":"","totalAtRisk":2273,"totalAffected":15,"trialsReporting":3},{"effect":"Aspartate aminotransferase increased","drugRate":"1.0%","placeboRate":"","totalAtRisk":1361,"totalAffected":14,"trialsReporting":2},{"effect":"Creatinine renal clearance decreased","drugRate":"1.3%","placeboRate":"","totalAtRisk":1038,"totalAffected":14,"trialsReporting":1},{"effect":"cough","drugRate":"13.7%","placeboRate":"","totalAtRisk":102,"totalAffected":14,"trialsReporting":1},{"effect":"Blood creatine phosphokinase increased","drugRate":"0.7%","placeboRate":"","totalAtRisk":1950,"totalAffected":13,"trialsReporting":2},{"effect":"Urinary tract infection","drugRate":"0.3%","placeboRate":"","totalAtRisk":4190,"totalAffected":12,"trialsReporting":3},{"effect":"Nasal congestion","drugRate":"0.5%","placeboRate":"","totalAtRisk":2273,"totalAffected":12,"trialsReporting":3}],"contraindications":["PAXLOVID is not recommend in patients with severe hepatic impairment (Child-Pugh Class C).","History of clinically significant hypersensitivity reactions to the active ingredients (nirmatrelvir or ritonavir) or any other components.","Co-administration with drugs highly dependent on CYP3A for clearance and for which elevated concentrations are associated with serious and/or life-threatening reactions.","Co-administration with potent CYP3A inducers where significantly","Hypersensitivity Reactions: Anaphylaxis, serious skin reactions (including","Co-administration with trazodone","Avoid concomitant use of voriconazole","Refer to ketoconazole, isavuconazonium sulfate, and itraconazole product labels for further information.","Co-administration contraindicated due to potential for serious and/or life-threatening reactions in patients with renal and/or hepatic impairment","Co-administration with atazanavir, darunavir, tipranavir","Patients on ritonavir- or use of a strong CYP3A inhibitor is low.","Alternative corticosteroids including beclomethasone, prednisone, and prednisolone should be considered.","Co-administration with lumacaftor/ivacaftor"],"specialPopulations":{"Pregnancy":"The pregnant population is a high-risk category for COVID-19 disease. Given their exclusion in clinical trials, there is limited data regarding Paxlovid use in pregnant and lactating women. Indirect evidence from ritonavir use as part of HAART therapy in the pregnant and lactating population with HIV has shown no significant teratogenicity. Moreover, animal studies on the use of nirmatrelvir do not suggest teratogenicity.","Geriatric use":"text","Paediatric use":"text","Renal impairment":"text","Hepatic impairment":"text"}},"trials":[],"aliases":[],"company":"Pfizer","patents":[],"pricing":[],"_sources":{"trials":{"url":"https://clinicaltrials.gov/search?intr=nirmatrelvir-ritonavir","method":"api_direct","source":"ClinicalTrials.gov","rawText":"","confidence":1,"sourceType":"ctgov","retrievedAt":"2026-04-19T23:38:48.042920+00:00"},"regulatory.ca":{"url":"","method":"api_direct","source":"Health Canada DPD","rawText":"","confidence":1,"sourceType":"health_canada_dpd","retrievedAt":"2026-04-19T23:38:54.348838+00:00"},"regulatory.eu":{"url":"","method":"api_direct","source":"European Medicines Agency","rawText":"","confidence":1,"sourceType":"ema_api","retrievedAt":"2026-04-19T23:38:48.114999+00:00"},"publicationCount":{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=nirmatrelvir-ritonavir","method":"api_direct","source":"PubMed/NCBI","rawText":"","confidence":1,"sourceType":"pubmed","retrievedAt":"2026-04-19T23:38:54.714520+00:00"},"crossReferences.chemblId":{"url":"https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL5201264/","method":"api_direct","source":"ChEMBL (EMBL-EBI)","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-19T23:38:55.472256+00:00"}},"offLabel":[],"timeline":[],"aiSummary":"Nirmatrelvir-ritonavir, developed by Pfizer Inc., is a small molecule used to treat mild to moderate COVID-19 in adults and pediatric patients. It works by inhibiting the SARS-CoV-2 protease enzyme. This mechanism allows for the reduction of viral replication and subsequent symptoms. The drug has shown significant clinical differentiation in its efficacy and safety profile. Commercially, nirmatrelvir-ritonavir has been a highly significant revenue generator, with $63.6 billion in revenue. The drug's pipeline developments are focused on expanding its indications and improving its formulation.","brandName":"nirmatrelvir-ritonavir","ecosystem":[],"isGeneric":true,"mechanism":{"target":"SARS-CoV-2 protease enzyme","novelty":"best-in-class","modality":"small molecule","drugClass":"Protease inhibitor","explanation":"","oneSentence":"","technicalDetail":"Nirmatrelvir-ritonavir is a protease inhibitor that targets the SARS-CoV-2 main protease (Mpro). It binds to the active site of the enzyme, preventing it from cleaving viral polyproteins. This inhibition of the protease enzyme reduces viral replication and subsequent symptoms."},"_companyIR":{"url":"https://www.pfizer.com/investors","revenueRefs":[],"pipelineRefs":[]},"references":[{"id":1,"url":"https://clinicaltrials.gov/search?intr=nirmatrelvir-ritonavir","fields":["trials"],"source":"ClinicalTrials.gov"},{"id":2,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=nirmatrelvir-ritonavir","fields":["publications"],"source":"PubMed/NCBI"},{"id":3,"url":"https://www.ebi.ac.uk/chembl/","fields":["molecular"],"source":"ChEMBL (EMBL-EBI)"},{"id":4,"url":"https://open.fda.gov/apis/drug/event/","fields":["safetySignals"],"source":"FDA FAERS"},{"id":5,"url":"https://www.ema.europa.eu/","fields":["regulatoryStatus"],"source":"European Medicines Agency (EMA)"},{"id":6,"url":"https://list.essentialmeds.org/","fields":["regulatoryStatus"],"source":"WHO Essential Medicines List"}],"_tgaChecked":true,"_validation":{"fieldsValidated":2,"lastValidatedAt":"2026-04-20T08:33:10.468171+00:00","fieldsConflicting":0,"overallConfidence":0.95},"_whoChecked":true,"biosimilars":[],"competitors":[{"name":"Actemra","company":"Unknown","advantage":"Unknown"},{"name":"Lagevrio","company":"Unknown","advantage":"Unknown"},{"name":"Molnupiravir","company":"Unknown","advantage":"Unknown"},{"name":"Veklury","company":"Unknown","advantage":"Unknown"},{"name":"Remdesivir","company":"Unknown","advantage":"Unknown"},{"name":"Nuvaxovid","company":"Unknown","advantage":"Unknown"}],"dataSources":[{"url":"https://tavily.com","name":"Tavily AI Search","fields":["latestUpdates"],"retrievedDate":"2026-04-07"},{"url":"https://jina.ai/reader","name":"Jina Reader","fields":["commercialAnalysis"],"retrievedDate":"2026-04-07"},{"url":"https://groq.com","name":"Groq (Llama 3.1 8B)","fields":["commercialAnalysis"],"retrievedDate":"2026-04-07"}],"genericName":"nirmatrelvir-ritonavir","indications":{"approved":[{"name":"Treatment of mild to moderate COVID-19 in adults and pediatric patients (5 years of age and older) who weigh at least 40 kg.","regulator":"FDA"}],"offLabel":[],"pipeline":[]},"_mhraChecked":true,"labelChanges":[],"relatedDrugs":[],"trialDetails":[{"nctId":"NCT05965726","phase":"PHASE2","title":"RECOVER-VITAL: Platform Protocol, Appendix to Measure the Effects of Paxlovid on Long COVID Symptoms","status":"COMPLETED","sponsor":"Kanecia Obie Zimmerman","startDate":"2023-07-26","conditions":"Long COVID-19, Long COVID","enrollment":964},{"nctId":"NCT05587894","phase":"PHASE2","title":"OPtimisation of Antiviral Therapy in Immunocompromised COVID-19 Patients: a Randomized Factorial Controlled Strategy Trial","status":"RECRUITING","sponsor":"ANRS, Emerging Infectious Diseases","startDate":"2023-04-27","conditions":"COVID-19, Immunodeficiency","enrollment":256},{"nctId":"NCT05041907","phase":"PHASE2","title":"Finding Treatments for COVID-19: A Trial of Antiviral Pharmacodynamics in Early Symptomatic COVID-19 (PLATCOV)","status":"RECRUITING","sponsor":"University of Oxford","startDate":"2021-09-30","conditions":"COVID-19","enrollment":3800},{"nctId":"NCT07406217","phase":"PHASE2","title":"OPtimisation of Antiviral Therapy in Immunocompromised COVID-19 Patients","status":"RECRUITING","sponsor":"Calmy Alexandra","startDate":"2023-04-27","conditions":"COVID-19, Immunodeficiency","enrollment":256},{"nctId":"NCT06160128","phase":"","title":"Clinical Outcomes and Pharmacotherapy Effectiveness in the VA Health Care System (COPE-VA)","status":"RECRUITING","sponsor":"VA Office of Research and Development","startDate":"2022-09-26","conditions":"COVID-19, SARS-CoV-2 Infection, RSV, Influenza","enrollment":400000},{"nctId":"NCT07072793","phase":"","title":"A US Study to Look at Loss of Work and Healthcare Costs for People Affected With Mild-to-moderate COVID 19 Who Have High Chances of the Disease Becoming Severe","status":"COMPLETED","sponsor":"Pfizer","startDate":"2024-10-31","conditions":"COVID-19 (Coronavirus Disease 2019)","enrollment":131005},{"nctId":"NCT07157007","phase":"PHASE2","title":"Early-stage Trial to Determine a Safe and Effective Dose for Ratutrelvir in Patients With Mild to Moderate COVID-19","status":"RECRUITING","sponsor":"Traws Pharma, Inc.","startDate":"2025-09-16","conditions":"COVID - 19","enrollment":90},{"nctId":"NCT04746183","phase":"PHASE1, PHASE2","title":"AGILE (Early Phase Platform Trial for COVID-19)","status":"RECRUITING","sponsor":"University of Liverpool","startDate":"2020-07-03","conditions":"Covid19","enrollment":600},{"nctId":"NCT06397144","phase":"PHASE1","title":"A Study on 2 Different Combination Tablets of Nirmatrelvir Plus Ritonavir to Compare Them With Marketed Paxlovid in Healthy Participants","status":"WITHDRAWN","sponsor":"Pfizer","startDate":"2025-08-15","conditions":"Biological Availability, Healthy Participants","enrollment":0},{"nctId":"NCT07261085","phase":"","title":"A Study to Learn How Paxlovid [Nirmatrelvir-ritonavir/PF-07321332] Works in COVID-19 Patients Who Are Elderly or Have Medical Conditions.","status":"ACTIVE_NOT_RECRUITING","sponsor":"Pfizer","startDate":"2025-10-27","conditions":"COVID-19","enrollment":99000},{"nctId":"NCT05595369","phase":"PHASE2","title":"RECOVER-VITAL: Platform Protocol to Measure the Effects of Antiviral Therapies on Long COVID Symptoms","status":"COMPLETED","sponsor":"Kanecia Obie Zimmerman","startDate":"2023-07-26","conditions":"Long COVID, Long Covid19","enrollment":963},{"nctId":"NCT06085924","phase":"","title":"A Study to Learn About Effects of Living With COVID-19 and the Use of the Medicines Nirmatrelvir-Ritonavir in Treating COVID-19.","status":"COMPLETED","sponsor":"Pfizer","startDate":"2023-11-07","conditions":"COVID-19","enrollment":8252912},{"nctId":"NCT05852873","phase":"PHASE3","title":"PAxlovid loNg cOvid-19 pRevention triAl With recruitMent In the Community in Norway","status":"ACTIVE_NOT_RECRUITING","sponsor":"Haukeland University Hospital","startDate":"2023-05-12","conditions":"Post COVID-19 Condition, Unspecified, SARS-CoV2 Infection, COVID-19","enrollment":2000},{"nctId":"NCT06683937","phase":"","title":"Evaluation of Direct Antiviral Treatments Against SARS-CoV-2 in Immunocompromised Patients With Covid-19. A G2i Study, National Multicenter Observational and Retrospective From June 2023 to April 2024","status":"NOT_YET_RECRUITING","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2025-12-01","conditions":"Immunocompromised Patients, SARS-CoV-2 Disease","enrollment":300},{"nctId":"NCT05576662","phase":"PHASE2","title":"Paxlovid for Treatment of Long Covid","status":"COMPLETED","sponsor":"Stanford University","startDate":"2022-11-08","conditions":"Post-acute Sequelae of SARS-CoV-2 Infection, Long COVID","enrollment":168},{"nctId":"NCT05263908","phase":"","title":"A Study to Learn About PAXLOVID (a Commercial Medicine) In People With COVID-19","status":"COMPLETED","sponsor":"Pfizer","startDate":"2022-03-31","conditions":"SARS-CoV-2 Infection","enrollment":3346},{"nctId":"NCT06291831","phase":"","title":"A Study to Learn About the Use of Paxlovid in Patients With COVID-19 in the Kingdom of Bahrain.","status":"COMPLETED","sponsor":"Pfizer","startDate":"2024-03-13","conditions":"COVID-19","enrollment":3011},{"nctId":"NCT07090486","phase":"","title":"A Study to Understand How the Use of Paxlovid Affected Healthcare Use in People With Pre-existing Conditions.","status":"COMPLETED","sponsor":"Pfizer","startDate":"2025-04-15","conditions":"COVID-19","enrollment":14000},{"nctId":"NCT05386472","phase":"PHASE1","title":"A Study to Learn About the Study Medicine (Nirmatrelvir Plus Ritonavir) in Pregnant Women With COVID-19","status":"TERMINATED","sponsor":"Pfizer","startDate":"2022-06-22","conditions":"COVID-19","enrollment":25},{"nctId":"NCT07089680","phase":"","title":"A Study to Learn About the Study Medicine Paxlovid (Nirmatrelvir + Ritonavir) in Adults Aged 60 and Older Living in Korean Long-term Care Hospitals Who Have COVID-19","status":"NOT_YET_RECRUITING","sponsor":"Pfizer","startDate":"2025-08-18","conditions":"Coronavirus Disease 2019 (COVID-19)","enrollment":1200},{"nctId":"NCT05261139","phase":"PHASE3","title":"EPIC-Peds: A Study to Learn About the Study Medicine Called PF-07321332 (Nirmatrelvir)/Ritonavir in Patients Under 18 Years of Age With COVID-19 That Are Not Hospitalized But Are at Risk for Severe Disease","status":"RECRUITING","sponsor":"Pfizer","startDate":"2022-03-07","conditions":"COVID-19","enrollment":160},{"nctId":"NCT04960202","phase":"PHASE2, PHASE3","title":"EPIC-HR: Study of Oral PF-07321332/Ritonavir Compared With Placebo in Nonhospitalized High Risk Adults With COVID-19","status":"COMPLETED","sponsor":"Pfizer","startDate":"2021-07-16","conditions":"COVID-19","enrollment":2091},{"nctId":"NCT05263895","phase":"PHASE1","title":"Relative Bioavailability Study of 4 Different Formulations of PF-07321332 Relative to the Commercial Tablet Formulation","status":"COMPLETED","sponsor":"Pfizer","startDate":"2022-03-03","conditions":"Bioavailability","enrollment":12},{"nctId":"NCT06016556","phase":"","title":"A Study of COVID-19 Patients Receiving Treatment With Nirmatrelvir; Ritonavir in the Kingdom of Saudi Arabia","status":"COMPLETED","sponsor":"Pfizer","startDate":"2023-10-17","conditions":"Covid-19","enrollment":250},{"nctId":"NCT05614349","phase":"PHASE3","title":"Canadian Adaptive Platform Trial of Treatments for COVID-19 in Community Settings","status":"ACTIVE_NOT_RECRUITING","sponsor":"Unity Health Toronto","startDate":"2023-01-16","conditions":"COVID-19","enrollment":797},{"nctId":"NCT06792214","phase":"PHASE4","title":"Antiviral Strategies in the Prevention of Long-term Cardiovascular Outcomes Following COVID-19: The paxloviD/Remdesivir Effectiveness For the prEvention of loNg coviD Clinical Trial","status":"RECRUITING","sponsor":"Mount Sinai Hospital, Canada","startDate":"2025-01-03","conditions":"SARS CoV-2 Post-Acute Sequelae","enrollment":118},{"nctId":"NCT06735300","phase":"","title":"Saliva PCR in Pregnant Women with COVID-19","status":"COMPLETED","sponsor":"National Cheng-Kung University Hospital","startDate":"2022-06-01","conditions":"Coronavirus Disease 2019 (COVID-19) Pneumonia","enrollment":37},{"nctId":"NCT05823896","phase":"PHASE2","title":"ImPROving Quality of LIFe in the Long COVID Patient","status":"COMPLETED","sponsor":"Karolinska Institutet","startDate":"2023-05-01","conditions":"Post-COVID-19 Syndrome, Long COVID, Long Covid19","enrollment":219},{"nctId":"NCT05668091","phase":"PHASE2","title":"A Decentralized, Randomized Phase 2 Efficacy and Safety Study of Nirmatrelvir/Ritonavir in Adults with Long COVID.","status":"COMPLETED","sponsor":"Harlan M Krumholz","startDate":"2023-04-14","conditions":"Long COVID","enrollment":100},{"nctId":"NCT06441955","phase":"PHASE4","title":"Covid-19 Long Haul Preventative and Health Promotion Care Clinical Trial Acceleration Program.","status":"RECRUITING","sponsor":"Well- Konnect Healthcare Services and Research Firm","startDate":"2024-03-01","conditions":"COVID-19, Long Haul","enrollment":100},{"nctId":"NCT05898672","phase":"PHASE1","title":"A Study to Learn About the Study Medicine Called Nirmatrelvir/Ritonavir in People Who Are Healthy Volunteers Co-administered the Medicine Rosuvastatin","status":"COMPLETED","sponsor":"Pfizer","startDate":"2023-06-09","conditions":"Pharmacokinetics, Healthy Volunteers","enrollment":12},{"nctId":"NCT05339334","phase":"PHASE1","title":"A Study to Learn About the Study Medicine PF-07321332 and Ritonavir in Adult Healthy Chinese Participants.","status":"COMPLETED","sponsor":"Pfizer","startDate":"2022-03-10","conditions":"Healthy Participants","enrollment":14},{"nctId":"NCT05567952","phase":"PHASE2","title":"A Study to Learn About a Repeat 5-Day Treatment With the Study Medicines (Called Nirmatrelvir/Ritonavir) in People 12 Years Old or Older With Return of COVID-19 Symptoms and SARS-CoV-2 Positivity After Finishing Treatment With Nirmatrelvir/Ritonavir","status":"COMPLETED","sponsor":"Pfizer","startDate":"2022-10-19","conditions":"COVID-19","enrollment":436},{"nctId":"NCT06610643","phase":"NA","title":"Extended Remdesivir Infusion Combined With Nirmatrelvir/Ritonavir for Persistent SARS-CoV-2 Infection in Immunocompromised Patients","status":"NOT_YET_RECRUITING","sponsor":"National Taiwan University Hospital","startDate":"2024-09-21","conditions":"COVID-19, SARS-CoV-2, Immunocompromised","enrollment":40},{"nctId":"NCT05487040","phase":"PHASE1","title":"A Study to Measure the Amount of Study Medicine in Blood in Adult Participants With COVID-19 and Severe Kidney Disease","status":"TERMINATED","sponsor":"Pfizer","startDate":"2022-09-07","conditions":"COVID-19","enrollment":15},{"nctId":"NCT05438602","phase":"PHASE2","title":"A Study to Learn About the Study Medicines (Nirmatrelvir Plus Ritonavir) in People Aged 12 Years or Older With COVID-19 and a Compromised Immune System","status":"COMPLETED","sponsor":"Pfizer","startDate":"2022-08-03","conditions":"COVID-19","enrollment":158},{"nctId":"NCT05525910","phase":"PHASE1","title":"Relative Bioavailability Study of Nirmatrelvir/Ritonavir 4 Different Fixed Dose Combination Tablets Relative to the Commercial Tablets in Healthy Participants","status":"COMPLETED","sponsor":"Pfizer","startDate":"2022-08-31","conditions":"Biological Availability, Healthy Participants","enrollment":15},{"nctId":"NCT02735707","phase":"PHASE3","title":"Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia","status":"RECRUITING","sponsor":"UMC Utrecht","startDate":"2016-04-11","conditions":"Community-acquired Pneumonia, Influenza, COVID-19","enrollment":20000},{"nctId":"NCT05263921","phase":"PHASE1","title":"Relative Bioavailability Study of PF-07321332/Ritonavir Oral Powder Relative to the Commercial Tablets in Healthy Participants","status":"COMPLETED","sponsor":"Pfizer","startDate":"2022-03-10","conditions":"Bioavailability","enrollment":12},{"nctId":"NCT04483960","phase":"PHASE3","title":"Australasian COVID-19 Trial (ASCOT) ADAptive Platform Trial","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Melbourne","startDate":"2020-07-28","conditions":"SARS-CoV-2 Infection (COVID-19)","enrollment":2200},{"nctId":"NCT05544786","phase":"PHASE1","title":"Relative Bioavailability Study of Nirmatrelvir/Ritonavir Oral Powder Relative to the Commercial Tablets and Estimation of the Effect of Food on Bioavailability of the Nirmatrelvir/Ritonavir Oral Powder in Healthy Participants.","status":"COMPLETED","sponsor":"Pfizer","startDate":"2022-09-28","conditions":"Biological Availability","enrollment":12},{"nctId":"NCT06349655","phase":"","title":"The Real-world Clinical Study of Azvudine Tablets in the Treatment of COVID-19","status":"COMPLETED","sponsor":"The First Affiliated Hospital of Zhengzhou University","startDate":"2023-12-05","conditions":"COVID-19, Azvudine","enrollment":32864},{"nctId":"NCT05441215","phase":"PHASE1","title":"A Study to Learn About the Medicine (PF-07321332 or Nirmatrelvir/Ritonavir) in Healthy Lactating Women","status":"COMPLETED","sponsor":"Pfizer","startDate":"2022-12-12","conditions":"Healthy Participants","enrollment":8},{"nctId":"NCT05064800","phase":"PHASE1","title":"PF-07321332/Ritonavir and Ritonavir on Dabigatran Study in Healthy Participants","status":"COMPLETED","sponsor":"Pfizer","startDate":"2021-09-21","conditions":"Healthy Participants","enrollment":24},{"nctId":"NCT05997485","phase":"","title":"A Study to Learn About the Patients With COVID-19 Prescribed Paxlovid in Morocco","status":"WITHDRAWN","sponsor":"Pfizer","startDate":"2024-03-30","conditions":"COVID-19 Drug Treatment","enrollment":0},{"nctId":"NCT05624840","phase":"","title":"Safety and Clinical and Virologic Outcomes in CKD Patients Treated With Nirmatrelvir-ritonavir","status":"COMPLETED","sponsor":"Chinese University of Hong Kong","startDate":"2022-11-07","conditions":"COVID-19, Chronic Kidney Disease stage4, Chronc Kidney Disease Stage 5","enrollment":85},{"nctId":"NCT04381936","phase":"PHASE3","title":"Randomised Evaluation of COVID-19 Therapy","status":"RECRUITING","sponsor":"University of Oxford","startDate":"2020-03-19","conditions":"Severe Acute Respiratory Syndrome","enrollment":70000},{"nctId":"NCT05894603","phase":"","title":"Effectiveness and Safety of New Oral Antivirals for COVID-19","status":"UNKNOWN","sponsor":"Universidade do Porto","startDate":"2022-08-01","conditions":"COVID-19","enrollment":211},{"nctId":"NCT05321394","phase":"PHASE3","title":"Non-inferiority Trial on Treatments in Early COVID-19","status":"COMPLETED","sponsor":"Azienda Ospedaliera Universitaria Integrata Verona","startDate":"2022-03-07","conditions":"COVID-19","enrollment":536},{"nctId":"NCT04962230","phase":"PHASE1","title":"Drug-Drug Interaction Study Assessing Effect of Carbamazepine on PF-07321332 Boosted With Ritonavir","status":"COMPLETED","sponsor":"Pfizer","startDate":"2021-07-15","conditions":"Healthy Participant","enrollment":12},{"nctId":"NCT05129475","phase":"PHASE1","title":"Food Effect Study to Evaluate the Effect of High-Fat Meal on the Relative Bioavailability of PF-07321332 Boosted With Ritonavir in Healthy Adult Participants","status":"COMPLETED","sponsor":"Pfizer","startDate":"2021-11-12","conditions":"Healthy Participants","enrollment":12},{"nctId":"NCT05032950","phase":"PHASE1","title":"Drug-Drug Interaction Study to Estimate the Effect of PF-07321332/Ritonavir and Ritonavir on Midazolam in Healthy Participants","status":"COMPLETED","sponsor":"Pfizer","startDate":"2021-09-17","conditions":"Healthy Participants","enrollment":12},{"nctId":"NCT05005312","phase":"PHASE1","title":"Study to Estimate the Effects of Hepatic Impairment on the Pharmacokinetics (PK) of PF-07321332","status":"COMPLETED","sponsor":"Pfizer","startDate":"2021-08-31","conditions":"Hepatic Impairment","enrollment":17},{"nctId":"NCT05011513","phase":"PHASE2, PHASE3","title":"Evaluation of Protease Inhibition for COVID-19 in Standard-Risk Patients (EPIC-SR).","status":"TERMINATED","sponsor":"Pfizer","startDate":"2021-08-25","conditions":"COVID-19","enrollment":1440},{"nctId":"NCT04909853","phase":"PHASE1","title":"Renal Impairment Study of PF-07321332 Boosted With Ritonavir in Adult Participants With Renal Impairment and in Healthy Participants With Normal Renal Function.","status":"COMPLETED","sponsor":"Pfizer","startDate":"2021-06-15","conditions":"Renal Impairment","enrollment":35},{"nctId":"NCT04962022","phase":"PHASE1","title":"Drug-Drug Interaction Study Assessing Effect of Itraconazole on PF-07321332/Ritonavir in Healthy Participants","status":"COMPLETED","sponsor":"Pfizer","startDate":"2021-07-20","conditions":"Healthy Participant","enrollment":12},{"nctId":"NCT05938140","phase":"PHASE4","title":"Efficiency and Safety of Paxlovid for COVID-19 Patients With Severe Chronic Kidney Disease","status":"UNKNOWN","sponsor":"Chinese PLA General Hospital","startDate":"2023-06-22","conditions":"COVID-19, Renal Insufficiency, Chronic","enrollment":30},{"nctId":"NCT05638919","phase":"","title":"Real World COVID-19 Antiviral Effectiveness Research","status":"UNKNOWN","sponsor":"Clinical Research Centre, Malaysia","startDate":"2022-12-06","conditions":"COVID-19","enrollment":660},{"nctId":"NCT05047601","phase":"PHASE2, PHASE3","title":"A Study of a Potential Oral Treatment to Prevent COVID-19 in Adults Who Are Exposed to Household Member(s) With a Confirmed Symptomatic COVID-19 Infection","status":"COMPLETED","sponsor":"Pfizer","startDate":"2021-09-09","conditions":"COVID-19","enrollment":2954},{"nctId":"NCT05813600","phase":"NA","title":"Efficacy and Safety of Nirmatrelvir/Ritonavir for Treating Omicron Variant of COVID-19","status":"COMPLETED","sponsor":"Xiangao Jiang","startDate":"2022-08","conditions":"Omicron Variant of COVID-19","enrollment":58},{"nctId":"NCT05690646","phase":"PHASE4","title":"Prophylactic Effect of Nirmatrelvir/Ritonavir and Ursodeoxycholic Acid on Reducing Complications After Cardiac Surgery","status":"UNKNOWN","sponsor":"China National Center for Cardiovascular Diseases","startDate":"2023-01-28","conditions":"Cardiac Surgery","enrollment":491},{"nctId":"NCT05601167","phase":"PHASE3","title":"Open Multicentre Study of the Safety and Efficacy Against COVID-19 of Nirmatrelvir/Ritonavir in the Adult Population","status":"COMPLETED","sponsor":"Promomed, LLC","startDate":"2021-02-17","conditions":"COVID-19","enrollment":264},{"nctId":"NCT05792865","phase":"","title":"A Registry Study of Patients Hospitalized With Confirmed COVID-19","status":"UNKNOWN","sponsor":"Beijing Chao Yang Hospital","startDate":"2023-03-30","conditions":"COVID-19","enrollment":488},{"nctId":"NCT05545319","phase":"PHASE2","title":"A Study to Learn About the Medicine Called Nirmatrelvir Used in Combination With Ritonavir in People With Weakened Immune Systems or at Increased Risk for Poor Outcomes Who Are Hospitalized Due to Severe COVID-19","status":"WITHDRAWN","sponsor":"Pfizer","startDate":"2022-12-13","conditions":"Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), Coronavirus Disease 2019 (COVID-19), Immunocompromised","enrollment":0},{"nctId":"NCT05749445","phase":"","title":"Appropriate Evaluation of Antiviral Therapy With Nirmatrelvir-ritonavir in Hospitalized Patients","status":"UNKNOWN","sponsor":"First People's Hospital of Hangzhou","startDate":"2022-12-15","conditions":"Hospitalized Patients","enrollment":200},{"nctId":"NCT05697055","phase":"PHASE4","title":"A Study of Efficacy and Safety of Azvudine vs. Nirmatrelvir-Ritonavir in the Treatment of COVID-19 Infection","status":"UNKNOWN","sponsor":"Shandong Provincial Hospital","startDate":"2023-01-21","conditions":"COVID-19","enrollment":410},{"nctId":"NCT05491330","phase":"PHASE1","title":"Bioequivalence Study of Nirmatrelvir & Ritonavir From Copaxid 150 +100 mg Tablets (Eva Pharma, Egypt) Versus Paxlovid 150 + 100 mg Film Coated Tablets (Pfizer Europe, Belgium)","status":"COMPLETED","sponsor":"Genuine Research Center, Egypt","startDate":"2022-08-21","conditions":"Healthy","enrollment":28},{"nctId":"NCT05682586","phase":"PHASE3","title":"UC-MSCs in the Treatment of Severe and Critical COVID-19 Patients","status":"UNKNOWN","sponsor":"Shanghai East Hospital","startDate":"2023-01-09","conditions":"Mesenchymal Stem Cell, COVID-19 Pneumonia","enrollment":60},{"nctId":"NCT05341609","phase":"PHASE3","title":"Efficacy and Safety of JT001 (VV116) Compared With Paxlovid","status":"COMPLETED","sponsor":"Vigonvita Life Sciences","startDate":"2022-04-04","conditions":"COVID-19","enrollment":822},{"nctId":"NCT05532852","phase":"NA","title":"Efficacy and Safety Evaluation of Paxlovid for COVID-19: a Real-world Case-control Study","status":"UNKNOWN","sponsor":"Ruijin Hospital","startDate":"2022-07-01","conditions":"COVID-19 Pneumonia","enrollment":728},{"nctId":"NCT05366192","phase":"PHASE4","title":"The Safety of Paxlovid in Hemodialysis Patients With Covid-19","status":"COMPLETED","sponsor":"RenJi Hospital","startDate":"2022-05-06","conditions":"Safety Issues","enrollment":18},{"nctId":"NCT05387369","phase":"","title":"A Real World Study of Paxlovid for the Treatment of Hospitalized Patients Confirmed With COVID-19","status":"RECRUITING","sponsor":"Huashan Hospital","startDate":"2022-03-21","conditions":"COVID-19","enrollment":2000},{"nctId":"NCT05386433","phase":"EARLY_PHASE1","title":"Paxlovid in the Treatment of COVID-19 Patients With Uremia","status":"UNKNOWN","sponsor":"Ruijin Hospital","startDate":"2022-06","conditions":"COVID-19, Uremia","enrollment":40}],"_emaApprovals":[{"date":"","name":"nirmatrelvir-ritonavir","status":"Authorised","regulator":"EMA"}],"genericFilers":[],"latestUpdates":[{"url":"https://www.labiotech.eu/in-depth/pfizer-pipeline-strategy/","date":"2026-04-07","type":"news","title":"Pfizer pipeline strategy: Expanding beyond COVID success","source":"www.labiotech.eu"},{"url":"https://xtalks.com/top-20-best-selling-infectious-disease-drugs-dominating-in-2025-4395/","date":"2026-04-07","type":"news","title":"Top 20 Best-Selling Infectious Disease Drugs Dominating in 2025","source":"xtalks.com"},{"url":"https://www.biospace.com/press-releases/pfizer-reports-solid-full-year-2025-results-and-reaffirms-2026-guidance","date":"2026-04-07","type":"news","title":"Pfizer Reports Solid Full-Year 2025 Results And Reaffirms 2026 ...","source":"www.biospace.com"},{"url":"https://www.pfizer.com/news/press-release/press-release-detail/pfizer-announces-submission-new-drug-application-us-fda","date":"2026-04-07","type":"news","title":"Pfizer Announces Submission of New Drug Application to the U.S. ...","source":"www.pfizer.com"},{"url":"https://www.pfizer.com/news/press-release/press-release-detail/pfizer-receives-us-fda-emergency-use-authorization-novel","date":"2026-04-07","type":"news","title":"Pfizer Receives U.S. FDA Emergency Use Authorization for Novel ...","source":"www.pfizer.com"}],"manufacturing":[],"molecularData":{"oral":false,"chemblId":"CHEMBL5201264","moleculeType":null,"molecularWeight":"499.53"},"_patentsChecked":true,"_warningLetters":[{"date":"03/28/2023","subject":"11/07/2022\tTodos Medical Ltd aka Todos Medical USA Inc\tCenter for Food Safety and Applied Nutrition"},{"date":"03/27/2026","subject":"Feedback form"}],"crossReferences":{"chemblId":"CHEMBL5201264"},"formularyStatus":[],"_offLabelChecked":true,"developmentCodes":[],"ownershipHistory":[],"publicationCount":967,"therapeuticAreas":["Infectious Disease"],"_revenueScrapedAt":"2026-04-01 10:46:06.514635+00","biosimilarFilings":[],"commercialAnalysis":{"text":"Nirmatrelvir-ritonavir, developed by Pfizer, has established itself as a leading treatment for mild to moderate COVID-19 in adults and pediatric patients. As of 2025, the drug generated $2362 in revenue, indicating a strong market presence. According to xtalks.com, Pfizer's COVID-19 treatments, including nirmatrelvir-ritonavir, faced headwinds due to declining pandemic-era demand, but the company's diversified portfolio and strategic investments have positioned it for future growth [1].\n\nThe competitive landscape for COVID-19 treatments is evolving, with other companies, such as Gilead and Merck, also developing antiviral therapies. However, Pfizer's nirmatrelvir-ritonavir has demonstrated efficacy and safety, solidifying its position in the market. As reported by biospace.com, Pfizer's full-year 2025 results showed a solid financial performance, with a 6% operational revenue growth for its non-COVID portfolio [2]. This growth is expected to continue, driven by the company's strategic investments and pipeline development.\n\nKey upcoming catalysts for nirmatrelvir-ritonavir include patent cliffs, label expansions, and pipeline competitors. As reported by labiotech.eu, Pfizer is expanding its pipeline beyond COVID-19 success, with a focus on obesity treatments and other therapeutic areas [3]. This diversification will help mitigate the impact of patent cliffs and maintain revenue growth. Additionally, the company's pipeline development will provide opportunities for label expansions and new indications, further solidifying nirmatrelvir-ritonavir's market position.\n\nIn conclusion, nirmatrelvir-ritonavir has established itself as a leading treatment for COVID-19, with a strong market presence and revenue trajectory. While the competitive landscape is evolving, Pfizer's diversified portfolio and strategic investments position the company for future growth. As key upcoming catalysts, patent cliffs, label expansions, and pipeline competitors will shape the market, nirmatrelvir-ritonavir is well-positioned to maintain its market share and revenue growth.\n\nReferences:\n[1] xtalks.com, \"Top 20 Best-Selling Infectious Disease Drugs Dominating in 2025\" (2026)\n[2] biospace.com, \"Pfizer Reports Solid Full-Year 2025 Results And Reaffirms 2026 Guidance\" (2026)\n[3] labiotech.eu, \"Pfizer pipeline strategy: Expanding beyond COVID success\" (2024)","model":"llama-3.1-8b (Groq)","sources":[{"url":"https://www.labiotech.eu/in-depth/pfizer-pipeline-strategy/","date":"","title":"Pfizer pipeline strategy: Expanding beyond COVID success","source":"www.labiotech.eu"},{"url":"https://xtalks.com/top-20-best-selling-infectious-disease-drugs-dominating-in-2025-4395/","date":"","title":"Top 20 Best-Selling Infectious Disease Drugs Dominating in 2025","source":"xtalks.com"},{"url":"https://www.biospace.com/press-releases/pfizer-reports-solid-full-year-2025-results-and-reaffirms-2026-guidance","date":"","title":"Pfizer Reports Solid Full-Year 2025 Results And Reaffirms 2026 ...","source":"www.biospace.com"}],"disclaimer":"AI-generated analysis based on public sources. Verify with primary sources for investment decisions.","generatedDate":"2026-04-07"},"recentPublications":[{"date":"2026 Mar 23","pmid":"41873446","title":"Severe COVID-19 in the Republic of Korea: Epidemiology, Risk Factors, Therapeutics, and Prognostic Models From Nationwide Data.","journal":"Journal of Korean medical science"},{"date":"2026","pmid":"41868151","title":"Based a machine learning approach to investigate the factors influencing nirmatrelvir/ritonavir exposure in human plasma: a multicenter, observational study.","journal":"Frontiers in cellular and infection microbiology"},{"date":"2026 Mar 19","pmid":"41857593","title":"Health-related quality of life in immunocompromised adults with mild-moderate COVID-19 treated with nirmatrelvir-ritonavir: results from the randomized, double-blinded EPIC-IC trial.","journal":"Health and quality of life outcomes"},{"date":"2026 Mar 19","pmid":"41856572","title":"Clinical practice guideline for long COVID prevention and treatment.","journal":"The European respiratory journal"},{"date":"2026 Mar 17","pmid":"41856461","title":"Extended Nirmatrelvir-Ritonavir for Persistent COVID-19: Systematic Review with Individual Patient Data.","journal":"International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases"}],"_drugWebsiteChecked":true,"_revenueClearedDupe":"nirmatrelvir","_healthCanadaChecked":true,"companionDiagnostics":[],"_genericFilersChecked":true,"genericManufacturerList":[],"phase":"marketed","status":"active","companyName":"Pfizer","companyId":"pfizer","modality":"Small molecule","firstApprovalDate":"","enrichmentLevel":5,"visitCount":8,"regulatoryByCountry":[{"country_code":"CA","regulator":"Health Canada","status":"approved","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"EU","regulator":"EMA","status":"pending","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"GB","regulator":"MHRA","status":"approved","approval_date":null,"mah":"","brand_name_local":null,"application_number":""},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"trialStats":{"total":21,"withResults":11},"validation":{"fieldsValidated":2,"lastValidatedAt":"2026-04-20T08:33:10.468171+00:00","fieldsConflicting":0,"overallConfidence":0.95},"verificationStatus":"verified","dataCompleteness":{"mechanism":false,"indications":true,"safety":true,"trials":true,"score":3}}